Blog Category

admin

Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021

,

/

13 July 2021

Biophytis Reinforces Leadership Teams with Three Senior Appointments

, , ,

/

8 July 2021

Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study

,

/

1 July 2021

Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021

,

/

1 July 2021

Biophytis announces new convertible bond financing for up to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million

,

/

21 June 2021

MAY 28, 2021

/

28 May 2021

Biophytis Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis

,

/

12 May 2021

Results of the Combined General Meeting on May 10, 2021

,

/

11 May 2021

Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders

,

/

30 April 2021

Biophytis receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD

,

/

29 April 2021

Biophytis – Convening of Another Combined General Meeting at a Later Date

,

/

27 April 2021

Biophytis gives operational perspectives on its Sarconeos (BIO101) ahead of its upcoming AGM on April 26, 2021 Read the presse release

,

/

26 April 2021